Protara Therapeutics (TARA) News Today

Protara Therapeutics, Inc. (NASDAQ: TARA) is drawing investor attention after a mix of encouraging clinical updates and bullish analyst revisions. The stock has been slipping overall today, but the latest news flow is mostly centered on its lead cell therapy, TARA-002, and continued optimism from Wall Street.

• Positive Sentiment: Protara said its mid-stage non-muscle invasive bladder cancer study showed durable treatment activity for TARA-002, which supports the drug’s clinical promise and may strengthen confidence in the program. Protara’s cell therapy shows treatment durability in mid-stage NMIBC study
• Positive Sentiment: HC Wainwright raised earnings estimates across several future years and maintained a Buy rating with a $27 price target, signaling confidence in Protara’s longer-term outlook.
• Positive Sentiment: Protara is also hosting a virtual investor webinar on TARA-002 and lymphatic malformations, which could help explain the opportunity around the program and keep the stock in focus. Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026
• Neutral Sentiment: The webinar and related materials reinforce that TARA-002 remains an investigational therapy in ongoing trials for both bladder cancer and rare pediatric lymphatic malformations, so execution and regulatory risk remain important.

Overall, TARA is being supported by encouraging clinical durability data and higher analyst forecasts, but the shares are still under pressure as investors weigh the risks typical of a clinical-stage biotech.